2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 690

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Abstract Number: 691

A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications
Abstract Number: 692

TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Abstract Number: 693

Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Abstract Number: 694

Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Abstract Number: 695

Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis
Abstract Number: 696

Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
Abstract Number: 697

Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Abstract Number: 698

Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 699

New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Abstract Number: 700

Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Abstract Number: 701

Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Abstract Number: 702

Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract Number: 703

Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Abstract Number: 704

Metabolomics Analysis of Insulin Resistance in Mild/Inactive Non-Diabetic Systemic Lupus Erythematosus Women

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].